
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1480661
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We report a case of a 60-year-old male who developed scattered erythema and papules on his left upper limb without any apparent cause six months ago. Initially, the patient underwent evaluations for various dermatological conditions, including eczema and psoriasis, while also being assessed for potential malignancies such as cutaneous lymphoma or sarcoidosis, but no definitive diagnosis was made. Over time, the patient's symptoms progressed, presenting as generalized erythema, papules, localized itching, and pain. Histopathological examination of the lesions diagnosed it as extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT). Subsequently, the patient was referred for staging via 18 F-FDG PET/CT, which revealed a widespread pattern of metabolically active lesions primarily affecting the skin and subcutaneous tissue of the limbs and buttocks. The patient received sequential treatment with P-GEMOX (gemcitabine, oxaliplatin, and Pegaspargase) and underwent clinical examination and follow-up whole-body 18 F-FDG PET/CT after six treatment cycles. The posttreatment PET/CT showed no abnormal 18 F-FDG uptake in the nasal cavity or skin, confirming clinical complete remission. Our case highlights the significant role of 18 F-FDG PET/CT in the clinical practice of ENKTCL-NT for initial staging and treatment response assessment. 1 metabolically active lesions primarily affecting the skin and 36 subcutaneous tissue of the limbs and buttocks.
Keywords: Lymphoma, Nasal type, 18 F-FDG, PET/CT, therapy
Received: 14 Aug 2024; Accepted: 10 Mar 2025.
Copyright: © 2025 Liu and Pei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xu-Sheng Liu, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.